3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
7
Breast Neoplasms
3
Zollinger-Ellison Syndrome
1
Triple Negative Breast Neoplasms
1
Stomach Ulcer
1
Solid Tumours
1
Solid Tumor
1
Prostate Cancer Patients
1
Pharmacokinetics of MDV3100
1
Ovarian Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Hodgkin Disease
1
Healthy Adult Participants
1
Esophagitis, Peptic
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Medullary
1
Breast Neoplasms, Male
1
Advanced Solid Tumours
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Adult Solid Neoplasm
1
Interventions
vandetanib
2
cabozantinib
2
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
Everolimus
2
veliparib
1
vatalanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
temsirolimus
1
sargramostim
1
pentetreotide
1
mercaptoundecahydrododecaborate
1
gallium Ga 68 dotatate
1
fludarabine
1
cixutumumab
1
Vinorelbine
1
Temozolomide
1
Specimen Handling
1
Sirolimus
1
Semaxinib
1
Salts
1
Ranitidine
1
Paclitaxel
1
Omeprazole
1
Octreotide
1
Nivolumab
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
High-Energy Shock Waves
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Medullary
×
Omeprazole
×
Clear all
NCT01539655
2017-05-02
Vandetanib
Sanofi
Phase 1
Completed
34 enrolled